AstraZeneca Results Presentation Deck

AstraZeneca in Breast Cancer Ambition to eliminate breast cancer as a cause of death established SoC Est. epi (G7) HER2-positive 15-20% HR-positive 65-75% HER2-low 60% TNBC 10-15% === HER2-low 35% gBRCAm 5% of HR-positive 15% of TNBC Neoadjuvant Enhertu +/- THP DESTINY-Breast11 Early 540k Adjuvant NST→ residual disease → Enhertu DESTINY-Breast05 Low risk Current SoC drives good outcomes for patients with low risk HR-positive eBC CTX AI (+/- CDK4/6i) → camizestrant CAMBRIA-1 NST → residual disease → Dato-DXd +/- Imfinzi TROPION-Breast03 CTX→ Lynparza OlympiA RECRURENCE ESR1m PD-L1- 60% 1st line 125k Enhertu DESTINY-Breast09 camizestrant + CDK4/6i SERENA-4 CDK4/6i + AI → CDK4/6i + camizestrant SERENA-6 capivasertib + Faslodex + CDK4/6i CAPItello292 capivasertib + paclitaxel CAPItello290 Dato-DXd TROPION-Breast02 HER2-low Metastatic 2nd line HER2 90k Enhertu DESTINY-Breast03 capivasertib + Faslodex CAPItello291 Enhertu DESTINY-Breast06 Lynparza OlympiAD HER2-low APPENDIX | Oncology tumour maps 3rd line 65k 4th line + Enhertu DESTINY-Breast02 55k Dato-DXd TROPION-Breast01 Enhertu DESTINY-Breast04 All numbers are approximate. Illustrative settings and populations, not to scale. 1/2/3/4L = 1st/2nd/3rd/4th-line; est epi (G7) = estimated epidemiology across G7 (US, EU5, JP for drug treated patients. HER2 = human epidermal growth factor receptor 2; THP = docetaxel, trastuzumab, and pertuzumab;NST = neoadjuvant systemic treatment; HR = hormone receptor; SoC = standard of care; CTXx = chemotherapy; Al = aromatase inhibitor; CDK4/6i = cyclin-dependent kinase 4 and 6 inhibitor; ESR1m = oestrogen receptor 1 gene mutation; Dato-DXd = datopotamab deruxtecan; TNBC = triple negative breast cancer; PD-L1 = programmed cell death ligand 1; gBRCAm = germline BRCA-mutated. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Merck & Co., Inc. (Lynparza).

View entire presentation